SCHEMBL5260815

SCHEMBL5260815

CSc1nccc(N(C)c2cc(Cl)nc(-c3ccccc3)c2)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CSNK1E P49674 1/20 0.39
▸ KDM4E B2RXH2 5/20 0.37
▸ HSP90AA1 P07900 1/20 0.37
▸ HSP90AB1 P08238 1/20 0.37
▸ LMNA P02545 3/20 0.36
▸ MEN1 O00255 5/20 0.36
▸ KMT2A Q03164 5/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ L3MBTL1 Q9Y468 3/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ ALDH1A1 P00352 3/20 0.35
▸ HPGD P15428 3/20 0.35
▸ MAPK13 O15264 1/20 0.34
▸ MAPK12 P53778 1/20 0.34
▸ MAPK11 Q15759 1/20 0.34
▸ MAPK14 Q16539 1/20 0.34
▸ MAPT P10636 2/20 0.34
▸ TP53 P04637 1/20 0.34
▸ THRB P10828 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5913757 0.86 LMNA (0.40) KDM4ELMNAMEN1KMT2ASMN1; SMN2
SCHEMBL5914109 0.77 MEN1 (0.41) CSNK1EKDM4EHSP90AA1HSP90AB1LMNA
SCHEMBL5913956 0.77 NPSR1 (0.44) CSNK1EKDM4EHSP90AA1LMNAMEN1
SCHEMBL5914199 0.74 CSNK1E (0.38) CSNK1EKDM4ELMNAMEN1KMT2A
SCHEMBL6415711 0.74 CSNK1E (0.43) CSNK1EKDM4ELMNAMEN1KMT2A
SCHEMBL6419066 0.73 KDM4E (0.38) CSNK1EKDM4ELMNAMEN1KMT2A
SCHEMBL5913947 0.72 LMNA (0.38) CSNK1EKDM4ELMNAMEN1KMT2A
SCHEMBL5914335 0.72 IGF1R (0.41) KMT2AMAPTTP53
SCHEMBL3933161 0.72 DPP4 (0.34) CSNK1EKDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL5320096 0.71 BRD4 (0.37) CSNK1EKDM4EMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1794135-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE Amgen Inc. (US) 2007-06-13 — — EP disclosed
WO-2006037117-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2006-04-06 — — WO disclosed
US-20060069110-A1 Substituted heterocyclic compounds and methods of use AMGEN INC. 2006-03-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060069110-A1 Substituted heterocyclic compounds and methods of use MAPT, MYLK2, IAPP CSNK1E 2656/4885KDM4E 4000/4885HSP90AA1 1223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback